Sage raises $575m ahead of FDA review date for Zulresso - PMLiVE

Sage raises $575m ahead of FDA review date for Zulresso  PMLiVEIn just under three weeks, Sage Therapeutics should hear back from the FDA on its filing for new antidepressant Zulresso, and the company has just raised ...